REAGENTS FOR EMERGING INFLUENZA STRAINS

Safer alternatives to live virus for your avian influenza research

Ready-to-use Reagents for H5N1 Influenza Research

Research on emerging influenza strains presents challenges that may put this important work out of your reach. Attenuated influenza strains can be difficult to access and time-consuming to bank. BSL-3 facilities are unavailable to many.  

But did you know there’s an easier way to get started with microneutralization and HAI assays? With our non-replicative, BSL-2 safe reagents, your team can be running avian influenza assays in as little as 10 days.

Schematics of Influenza TiterSafe and RVP. Both particles have HA and NA proteins in a lipid bilayer surrounding a lentivirus core. RVPs contain a luciferase or GFP reporter gene; TiterSafe particles lack genetic information.
For your influenza research needs, we offer two easy-to-use reagents for fast results: Reporter Virus Particles (RVPs) for viral neutralization and infectivity assays, and TiterSafe™ for HAI assays. Both are available strain-matched to a variety of H5N1 and other emerging strains, and they’re ready to ship.

Influenza TiterSafe for HAI Assays

TiterSafe is a cost-effective reagent that safely replaces live influenza virus in HAI assays. It arrives ready to use, with viral titers that are equivalent to commercially available inactivated influenza virus 

Learn more about Titersafe

Interactions and the corresponding microtiter well results for three conditions in an HAI assay. RBC-only negative control, agglutination with a matrix of RBCs and TiterSafe particles, and agglutination inhibition with serum antibodies blocking interactions between TiterSafe particles and RBCs.
TiterSafe produces easy-to-read results in your existing HAI workflow

Influenza Reporter Virus Particles for Microneutralization Assays

Non-replicative Reporter Virus Particles (RVPs) are a safe, easy-to-use substitute for live virus in neutralization assays. When an RVP infects a cell, the reporter integrates into the cells genome. The cell then expresses the gene, producing an optical readout. Easy to read on standard equipment such as a microscope, flow cytometer, or luminescence plate reader, the optical reporter eliminates the need for staining or counting viral plaques. 

Learn more about Reporter Virus Particles

Neutralization assay setup in a 96-well plate. Step 1: add 2x dilutions of antibody or serum. Step 2: add pseudovirus and incubate. Step 3: Add equivalent of target cells. Step 4: Incubate 24 to 48 hours. Step 5: Analyze for reporter expression.
Influenza pseudovirus neutralization assay at a glance. RVPs are available with a GFP or luciferase reporter. Reporter expression indicates when cells have been infected successfully. GFP read-out can be assessed by microscopy or flow cytometry, and luciferase readout can be assessed by plate reader.

Emerging Influenza Strain Product Catalog

Influenza A Subtype
Strain Information
RVP Catalog No.
Titersafe Catalog No.
H5N1
Texas/37/2024
RVP-1218
H5N1
dairy_cattle/Texas/24-008749-003-original/202
RVP-1217
H5N1
American Wigeon/SC/22-000345-001/2021
RVP-1214
HAP-1214
H5N8
Astrakhan/3212/2020
RVP-1209
H7N9
Guangdong/17SF003/2016
RVP-1210
H7N9
Suzhou/3/2013
RVP-1204
H5N1
turkey/Turkey/1/2005
RVP-1208
H5N1
Indonesia/5/05
RVP-1201
H5N1
Vietnam/1194/2004
RVP-1207*
H5N1
Vietnam/1203/2004
RVP-1205
HAP-1205

*Available in GFP only

VIEW THE FULL RVP CATALOG

All of our virology catalog offerings are produced using ISO 9001-certified processes and QMS. Because we know your time is valuable, our experts are here to help make sure your experiments work the first time. 

Frequently Asked Questions

Yes! Because we want to support scientists at the cutting edge of influenza research, we offer free samples of our H5 and H7 reagents. But supplies are limited, so be sure to reach out as soon as you can.

Our Influenza RVP protocols for H5 and H7 subtypes are optimized for HEK-293T cells. If you don’t have access to these cells, we can recommend sources.

Here’s a link to our recommended TiterSafe HAI protocol. It requires 10% guinea pig red blood cells.

Yes, we regularly update our product catalogs. Our team closely monitors scientific literature and updates from public health authorities and prepares new strains accordingly. We are following all CDC avian flu updates to help inform the development of reagents for emerging influenza strains.  

Yes! We have years of experience working with pseudoviruses, and we can apply this expertise to your custom influenza strain project. Unlike with live viruses, exploring point mutations in non-replicative systems is safe, and it’s as easy as changing a few base pairs on a DNA plasmid. Contact us to learn more. 

Yes! We offer influenza pseudovirus neutralization assay services for antibodies and animal samples. Results are available in as little as 4-6 weeks from receipt of samples. All samples must be heat-inactivated and/or be accompanied by appropriate health and safety certifications.